Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , AGCO ( NYSE:AGCO )
U.S. stocks were higher, with the Nasdaq Composite gaining around 150 points on Thursday. Shares of Roblox Corporation RBLX rose sharply during Thursday's session after the company reported better-than-expected second-quarter sales results and raised its FY25 sales guidance.
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
FDA Approves Apellis' Empaveli, Marks Key Milestone - Apellis Pharmaceuticals ( NASDAQ:APLS )
Empaveli cut proteinuria by 68% in C3G and IC-MPGN patients in a six-month trial. 71% of patients on Empaveli had complete clearance of C3 deposits. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.
FDA Approves Apellis' EMPAVELI® ( pegcetacoplan ) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - Apellis Pharmaceuticals ( NASDAQ:APLS )
Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and post-transplant C3G disease recurrence
FDA Approves Apellis' EMPAVELI® ( pegcetacoplan ) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
WALTHAM, Mass., July 28, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved EMPAVELI® ( pegcetacoplan ) as the first treatment for C3 glomerulopathy ( C3G ) or primary immune complex ...
Axsome Therapeutics ( AXSM ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., July 24, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
WALTHAM, Mass., July 24, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists ( ASRS ) Annual Scientific Meeting
WALTHAM, Mass., July 15, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists ( ASRS ) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, ...
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists ( ASRS ) Annual Scientific Meeting - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., July 15, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists ( ASRS ) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California.
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Why Is Kodiak Sciences ( KOD ) Up 10.5% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Apellis Pharmaceuticals ( APLS ) Up 7.2% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis and Sobi Announce EMPAVELI® ( pegcetacoplan ) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - Apellis Pharmaceuticals ( NASDAQ:APLS )
Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients New data presented at late-breaking session at the European Renal Association Congress Marketing applications for EMPAVELI are under review with the FDA and EMA
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., June 04, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Why Apellis Pharmaceuticals Wilted on Wednesday
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals ( NASDAQ: APLS ) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 ( SNPINDEX: ^GSPC ) ...
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Arista Networks ( NYSE:ANET ) , Apellis Pharmaceuticals ( NASDAQ:APLS )
U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company reported a first-quarter adjusted EPS miss.
Apellis Pharmaceuticals, Inc. ( APLS ) Reports Q1 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of -105.56% and 13.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics ( AXSM ) Reports Q1 Loss, Tops Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 36.51% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Rhythm Pharmaceuticals, Inc. ( RYTM ) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals, Inc. ( APLS ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately.
BioHarvest Sciences Inc. ( BHST ) Soars 5.2%: Is Further Upside Left in the Stock?
BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Apellis Pharmaceuticals ( NASDAQ:APLS )
The FDA granted Priority Review to Apellis' sNDA for Empaveli in C3G and IC-MPGN, with a PDUFA target action date of July 28, 2025. Phase 3 results showed Empaveli reduced proteinuria by 68% and stabilized kidney function ( p=0.03 ) in patients with C3G and IC-MPGN.
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® ( pegcetacoplan ) for C3G and Primary IC-MPGN - Apellis Pharmaceuticals ( NASDAQ:APLS )
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that the U.S.
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® ( pegcetacoplan ) for C3G and Primary IC-MPGN
WALTHAM, Mass., April 01, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted and granted Priority Review designation of the supplemental New Drug Application ( sNDA ) for EMPAVELI® ( ...
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Apellis Pharmaceuticals ( NASDAQ:APLS )
Apellis' Q4 Syfovre sales reached $167.8 million, with 94,000 doses delivered to physician practices. Survey results point to steadier growth for Syfovre/branded geographic atrophy products over the next 12 months.
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Apellis Pharmaceuticals ( NASDAQ:APLS )
Apellis Q4 loss was $0.29 per share, beating estimates of $0.37; revenue grew 45.2% to $212.5M, surpassing the $198.35M consensus. Syfovre sales hit $167.8M in Q4 and $611.9M for 2024, with over 510,000 injections administered since launch through December.
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Apellis Pharmaceuticals, Inc. ( APLS ) Reports Q4 Loss, Tops Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 25.64% and 8.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its fourth quarter and full year 2024 financial results and business highlights.
AnaptysBio, Inc. ( ANAB ) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. ( YMAB ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Apellis Pharmaceuticals, Inc. ( APLS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® ( pegcetacoplan ) for C3G and Primary IC-MPGN
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) and Sobi® ( STO:SOBI ) today announced the European Medicines Agency ( EMA ) has validated an indication extension application for Aspaveli® ( pegcetacoplan ) for the ...
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - Apellis Pharmaceuticals ( NASDAQ:APLS ) , Maplebear ( NASDAQ:CART )
SAN DIEGO, Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of MacroGenics, Inc. MGNX, Apellis Pharmaceuticals, Inc. APLS, Teradata Corporation TDC, and Maplebear ...
Apellis Receives Approval of SYFOVRE® ( pegcetacoplan ) in Australia for Geographic Atrophy ( GA ) - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria Market Set to Surge, Projected to Achieve a Remarkable Valuation of US$ 11.7 Billion by 2034 - Latest Insight by TMR
Wilmington, Delaware, Transparency Market Research Inc. -, Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- The global paroxysmal nocturnal hemoglobinuria ( PNH ) market, valued at approximately US$ 3.8 billion in 2023, is forecasted to experience substantial growth over the next decade, reaching an ...
Apellis Announces Keli Walbert to Join the Board of Directors - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WALTHAM, Mass., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as ...
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT.
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Apellis Pharmaceuticals ( NASDAQ:APLS )
WALTHAM, Mass., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT.
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Celcuity ( NASDAQ:CELC ) , Apellis Pharmaceuticals ( NASDAQ:APLS )
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. Shares of Mama's Creations Inc MAMA fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter EPS results.
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Agree Realty ( NYSE:ADC ) , Apellis Pharmaceuticals ( NASDAQ:APLS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JMP Securities analyst Mitch Germain downgraded Agree Realty Corporation ADC from Market Outperform to ...
Repligen ( RGEN ) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WALTHAM Mass., Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as ...
